OpenLB
Open Library of Bioscience
Advanced Search
Pharmaceutics
Jun 28, 2023;15 (7):

Localized Drug Delivery Systems: An Update on Treatment Options for Head and Neck Squamous Cell Carcinomas.

Arvind Hariharan, Simon D Tran
Author Information
  1. Arvind Hariharan: McGill Craniofacial Tissue Engineering and Stem Cells Laboratory, Faculty of Dental Medicine and Oral Health Sciences, McGill University, 3640 University Street, Montreal, QC H3A 0C7, Canada. ORCID
  2. Simon D Tran: McGill Craniofacial Tissue Engineering and Stem Cells Laboratory, Faculty of Dental Medicine and Oral Health Sciences, McGill University, 3640 University Street, Montreal, QC H3A 0C7, Canada. ORCID
PMID: 37514031 DOI: 10.3390/pharmaceutics15071844

Abstract

Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers in the world, with surgery, radiotherapy, chemotherapy, and immunotherapy being the primary treatment modalities. The treatment for HNSCC has evolved over time, due to which the prognosis has improved drastically. Despite the varied treatment options, major challenges persist. HNSCC chemotherapeutic and immunotherapeutic drugs are usually administered systemically, which could affect the patient's quality of life due to the associated side effects. Moreover, the systemic administration of salivary stimulating agents for the treatment of radiation-induced xerostomia is associated with toxicities. Localized drug delivery systems (LDDS) are gaining importance, as they have the potential to provide non-invasive, patient-friendly alternatives to cancer therapy with reduced dose-limiting toxicities. LDDSs involve directly delivering a drug to the tissue or organ affected by the disease. Some of the common localized routes of administration include the transdermal and transmucosal drug delivery system (DDSs). This review will attempt to explore the different treatment options using LDDSs for the treatment of HNSCC and radiotherapy-induced damage and their potential to provide a better experience for patients, as well as the obstacles that need to be addressed to render them successful.

Keywords

head and neck squamous cell carcinoma localized drug delivery nanoparticles penetration enhancers transdermal transmucosal

References

Nanomedicine. 2016 Jan;12(1):143-61 [PMID: 26410277]
Cell Rep. 2015 May 19;11(7):1018-30 [PMID: 25959818]
Oral Maxillofac Surg Clin North Am. 2019 Feb;31(1):145-154 [PMID: 30449525]
Colloids Surf B Biointerfaces. 2019 Jan 1;173:599-606 [PMID: 30352381]
Signal Transduct Target Ther. 2018 Mar 16;3:7 [PMID: 29560283]
Eur J Pharm Biopharm. 2015 May;92:42-8 [PMID: 25709060]
Saudi Pharm J. 2018 Jan;26(1):64-70 [PMID: 29379334]
Clin Transl Oncol. 2017 May;19(5):593-598 [PMID: 27853984]
N Engl J Med. 2016 Nov 10;375(19):1856-1867 [PMID: 27718784]
Carbohydr Polym. 2017 Oct 1;173:131-142 [PMID: 28732851]
Nanoscale. 2021 Oct 21;13(40):17168-17182 [PMID: 34636386]
Macromol Biosci. 2021 Jun;21(6):e2100039 [PMID: 33818918]
Acta Pharm. 2019 Jun 1;69(2):197-215 [PMID: 31259729]
Nanoscale Res Lett. 2021 Dec 5;16(1):173 [PMID: 34866166]
Chem Commun (Camb). 2015 Jan 28;51(8):1453-6 [PMID: 25493296]
Onco Targets Ther. 2020 Jan 29;13:889-902 [PMID: 32099393]
In Vivo. 2013 May-Jun;27(3):321-32 [PMID: 23606687]
J Clin Endocrinol Metab. 2000 May;85(5):1783-8 [PMID: 10843152]
Int J Health Sci (Qassim). 2016 Jul;10(3):425-35 [PMID: 27610066]
Iran J Public Health. 2018 Aug;47(8):1218-1219 [PMID: 30186799]
Support Care Cancer. 2020 Jun;28(6):2817-2828 [PMID: 31732852]
PLoS One. 2013 Apr 24;8(4):e61632 [PMID: 23637870]
Mol Pharm. 2020 Aug 3;17(8):3150 [PMID: 32672463]
Front Oncol. 2021 Sep 06;11:727433 [PMID: 34552878]
J Support Oncol. 2008 Jan;6(1):27-32 [PMID: 18257398]
Cancers (Basel). 2021 Mar 01;13(5): [PMID: 33804419]
Theranostics. 2016 Jul 18;6(11):1844-65 [PMID: 27570555]
J Natl Cancer Inst. 2009 Apr 1;101(7):498-506 [PMID: 19318632]
Cancer Sci. 2013 Mar;104(3):369-74 [PMID: 23216802]
Cochrane Database Syst Rev. 2013 Oct 05;(10):CD010270 [PMID: 24096644]
Biomaterials. 2016 Apr;85:232-45 [PMID: 26874285]
Nat Methods. 2016 Apr 28;13(5):405-14 [PMID: 27123816]
Cancer Lett. 2006 Jul 28;239(1):129-35 [PMID: 16198049]
J Control Release. 2005 Jan 3;101(1-3):151-62 [PMID: 15588901]
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):392-5 [PMID: 16246498]
J Pain Symptom Manage. 2003 Jun;25(6):555-8 [PMID: 12782436]
Front Oral Maxillofac Med. 2022 Sep;4: [PMID: 36105623]
J Laryngol Otol. 1994 Aug;108(8):663-5 [PMID: 7930915]
Anticancer Res. 2007 Sep-Oct;27(5A):3293-9 [PMID: 17970073]
Int J Nanomedicine. 2019 Sep 16;14:7549-7560 [PMID: 31571863]
Am J Cancer Res. 2020 Jan 01;10(1):350-364 [PMID: 32064172]
Cancers (Basel). 2011 Jul 15;3(3):2888-903 [PMID: 24212938]
Ann Oncol. 2020 Jul;31(7):942-950 [PMID: 32294530]
Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1141-1152 [PMID: 31063799]
Drug Deliv. 2016 Nov;24(1):792-799 [PMID: 28494629]
Nat Rev Mater. 2016 Dec;1(12): [PMID: 29657852]
Asia Pac J Clin Oncol. 2017 Apr;13(2):e48-e56 [PMID: 25347930]
J Biomater Sci Polym Ed. 2012;23(6):807-22 [PMID: 21418748]
Adv Drug Deliv Rev. 2020;160:234-243 [PMID: 33137363]
Br Dent J. 2007 Apr 14;202(7):E17; discussion 404-5 [PMID: 17273177]
Sci Rep. 2016 Apr 22;6:24629 [PMID: 27103308]
Cancer. 1992 Jan 15;69(2):285-91 [PMID: 1728358]
Lancet. 2019 Jan 5;393(10166):40-50 [PMID: 30449625]
Lancet Oncol. 2010 Jan;11(1):21-8 [PMID: 19897418]
Nucl Med Biol. 2009 Jul;36(5):515-24 [PMID: 19520292]
Nat Rev Clin Oncol. 2017 Aug;14(8):483-495 [PMID: 28290489]
ACS Nano. 2018 Oct 23;12(10):9693-9701 [PMID: 30183253]
Br J Pain. 2018 Aug;12(3):155-162 [PMID: 30057760]
Eur J Pharm Biopharm. 2015 Jun;93:52-79 [PMID: 25813885]
Adv Drug Deliv Rev. 2004 Mar 27;56(5):603-18 [PMID: 15019749]
Chin J Cancer. 2016 Apr 04;35:33 [PMID: 27044280]
Int J Nanomedicine. 2021 Apr 12;16:2761-2773 [PMID: 33880022]
J Colloid Interface Sci. 2012 Mar 15;370(1):58-66 [PMID: 22284577]
Trends Pharmacol Sci. 2009 Nov;30(11):592-9 [PMID: 19837467]
Pharm Res. 2013 Jul;30(7):1860-70 [PMID: 23549753]
Mol Cancer Ther. 2022 Apr 1;21(4):616-624 [PMID: 35086958]
Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):449-56 [PMID: 11380233]
Nat Rev Dis Primers. 2020 Nov 26;6(1):92 [PMID: 33243986]
Adv Drug Deliv Rev. 2012 Jan;64(1):16-28 [PMID: 21371513]
Int J Clin Pharmacol Ther. 2010 Feb;48(2):138-45 [PMID: 20137766]
Nanomedicine (Lond). 2019 Sep;14(18):2395-2408 [PMID: 31456475]
Biomater Sci. 2021 Mar 21;9(6):2103-2114 [PMID: 33475633]
Eur J Cancer. 2001 Nov;37(16):2015-22 [PMID: 11597379]
Pharmaceuticals (Basel). 2022 Jun 18;15(6): [PMID: 35745681]
Mol Cancer. 2020 Nov 12;19(1):160 [PMID: 33183286]
Oral Dis. 2022 Jan;28(1):164-172 [PMID: 33290635]
Cancers (Basel). 2022 Oct 31;14(21): [PMID: 36358782]
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Sep;82(3):268-75 [PMID: 8884824]
Recent Pat Nanotechnol. 2013 Jan;7(1):41-55 [PMID: 22946628]
Crit Rev Oncol Hematol. 2022 Jun;174:103679 [PMID: 35395371]
Eur J Cancer. 2016 Sep;65:121-9 [PMID: 27494037]
J Dent Res. 2018 Jun;97(6):601-602 [PMID: 29771196]
Cancer Invest. 2017 Jan 2;35(1):23-31 [PMID: 27892728]
Biomater Res. 2021 Jul 28;25(1):24 [PMID: 34321111]
Oncologist. 2007 Jun;12(6):738-47 [PMID: 17602063]
J Control Release. 2018 Aug 10;283:151-162 [PMID: 29864476]
J Urol. 2018 Sep;200(3):604-611 [PMID: 29654805]
Curr Med Res Opin. 2009 Nov;25(11):2805-15 [PMID: 19792837]
Clin Cancer Res. 2007 Aug 15;13(16):4928-33 [PMID: 17699873]
Nat Commun. 2022 Aug 17;13(1):4829 [PMID: 35977936]
Nanoscale. 2020 Sep 28;12(36):18885-18898 [PMID: 32902555]
J Pain Res. 2019 Jun 11;12:1847-1854 [PMID: 31354333]
Adv Pharm Bull. 2019 Jun;9(2):195-204 [PMID: 31380245]
Oncology (Williston Park). 2000 Nov;14(11A):135-50 [PMID: 11195407]
Support Care Cancer. 2015 May;23(5):1349-54 [PMID: 25351457]
Radiother Oncol. 2016 Jul;120(1):48-55 [PMID: 27342249]
Expert Opin Drug Deliv. 2009 May;6(5):543-52 [PMID: 19413461]
Br J Radiol. 2014 Jun;87(1038):20130490 [PMID: 24694358]
J Clin Med. 2020 Dec 18;9(12): [PMID: 33353023]
N Engl J Med. 2004 Dec 16;351(25):2590-8 [PMID: 15602019]
J Control Release. 2011 Jul 30;153(2):106-16 [PMID: 21300115]
J Nanobiotechnology. 2018 Oct 16;16(1):81 [PMID: 30326899]
Oncology. 2020;98(2):61-80 [PMID: 31846959]
Int J Mol Sci. 2021 Jan 12;22(2): [PMID: 33445616]
Ann Oncol. 2014 Jan;25(1):216-25 [PMID: 24256848]
Radiother Oncol. 2016 Feb;118(2):238-43 [PMID: 26589131]
J Pharm Pharmacol. 2015 Apr;67(4):473-85 [PMID: 25557808]
Auris Nasus Larynx. 2014 Oct;41(5):496-8 [PMID: 24931629]
J Clin Oncol. 2014 Sep 1;32(25):2735-43 [PMID: 25049329]
Int J Radiat Oncol Biol Phys. 2020 Feb 1;106(2):320-328 [PMID: 31669562]
Biomaterials. 2018 Nov;182:1-12 [PMID: 30096444]
ACS Appl Mater Interfaces. 2018 Oct 3;10(39):33060-33069 [PMID: 30204401]
Pharmaceutics. 2022 Oct 17;14(10): [PMID: 36297645]
Laryngoscope Investig Otolaryngol. 2019 Jan 03;4(1):49-56 [PMID: 30828619]
Bioact Mater. 2022 Sep 02;25:430-444 [PMID: 37056270]
Cancers (Basel). 2021 Nov 19;13(22): [PMID: 34830956]
Anticancer Res. 2007 Mar-Apr;27(2):1105-25 [PMID: 17465250]
Int J Pharm. 2017 Apr 15;521(1-2):92-101 [PMID: 28216463]
Pharmaceutics. 2018 Oct 25;10(4): [PMID: 30366360]
Drug Deliv Transl Res. 2022 Apr;12(4):758-791 [PMID: 33474709]
Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15027-32 [PMID: 15477593]
J Clin Oncol. 2014 Sep 10;32(26):2855-63 [PMID: 25113772]
Cancer. 2014 May 1;120(9):1433-40 [PMID: 24877167]
Materials (Basel). 2021 Jul 02;14(13): [PMID: 34279276]
J Pain Res. 2017 Aug 18;10:1963-1972 [PMID: 28860851]
Mar Drugs. 2022 May 20;20(5): [PMID: 35621986]
Nat Nanotechnol. 2021 Jul;16(7):748-759 [PMID: 34211166]
Mater Sci Eng C Mater Biol Appl. 2016 May;62:113-22 [PMID: 26952404]
J Clin Oncol. 2003 Jan 1;21(1):92-8 [PMID: 12506176]
Clin Cancer Res. 2005 Oct 15;11(20):7564-8 [PMID: 16243832]
Biomaterials. 2011 Oct;32(30):7600-8 [PMID: 21745689]
Pharmaceutics. 2015 Oct 22;7(4):438-70 [PMID: 26506371]
Biomaterials. 2014 Feb;35(7):2383-90 [PMID: 24345736]
Saudi Dent J. 2019 Oct;31(4):395-416 [PMID: 31700218]
J Dent Res. 1977 Feb;56(2):99-104 [PMID: 264889]
Drug Des Devel Ther. 2014 May 12;8:497-503 [PMID: 24872680]
Cancers (Basel). 2021 Jul 10;13(14): [PMID: 34298670]
Gels. 2022 Nov 15;8(11): [PMID: 36421563]
Cancer Res. 2003 Dec 15;63(24):8977-83 [PMID: 14695216]
J Dent Res. 2018 Oct;97(11):1252-1259 [PMID: 29634396]
Mol Pharm. 2020 Aug 3;17(8):3148 [PMID: 32678599]
Lancet. 2019 Jan 12;393(10167):156-167 [PMID: 30509740]
Int J Biol Macromol. 2019 Aug 15;135:1043-1051 [PMID: 31158424]
Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):944-8 [PMID: 12975266]
Colloids Surf B Biointerfaces. 2013 Oct 1;110:313-20 [PMID: 23732810]
Int Dent J. 2015 Oct;65(5):242-8 [PMID: 26362241]
Nat Rev Mater. 2021 Feb;6(2):103-106 [PMID: 36117545]
Lancet. 2019 Jan 5;393(10166):51-60 [PMID: 30449623]
Int J Mol Sci. 2019 Jan 28;20(3): [PMID: 30696017]
Nat Clin Pract Oncol. 2007 Mar;4(3):156-71 [PMID: 17327856]
Int J Nanomedicine. 2017 Dec 28;13:187-198 [PMID: 29343957]
Mater Today (Kidlington). 2021 Jul-Aug;47:206-222 [PMID: 36338772]
Int J Pharm. 2014 Jan 2;460(1-2):24-7 [PMID: 24219856]
Nat Biotechnol. 2006 Apr;24(4):455-60 [PMID: 16565728]
Mol Syst Biol. 2005;1:2005.0010 [PMID: 16729045]
Pharmaceutics. 2019 Jun 30;11(7): [PMID: 31262096]
Adv Drug Deliv Rev. 2020 Jan 1;153:87-108 [PMID: 32497707]
Indian J Dent Res. 2020 Nov-Dec;31(6):963-966 [PMID: 33753669]
Br J Pharmacol. 2015 May;172(9):2179-209 [PMID: 25560046]
Drug Dev Ind Pharm. 2008 Jan;34(1):107-15 [PMID: 18214762]
Clin Transl Radiat Oncol. 2021 Nov 26;32:59-68 [PMID: 34935776]
Jpn J Clin Oncol. 2010 Apr;40(4):307-12 [PMID: 20042478]
J Nanosci Nanotechnol. 2015 Jan;15(1):781-91 [PMID: 26328442]
PLoS One. 2012;7(4):e33860 [PMID: 22529899]
Cancer Res. 2018 Nov 1;78(21):6308-6319 [PMID: 30224374]
Int J Part Ther. 2021 Sep 14;8(2):51-61 [PMID: 34722811]
Acta Biomater. 2017 Jan 15;48:247-257 [PMID: 27769943]
Cancer Nurs. 2015 Jul-Aug;38(4):322-9 [PMID: 25232958]
Int J Hyperthermia. 2021;38(1):479-487 [PMID: 33730965]
Eur J Clin Pharmacol. 1972 Jun;4(3):137-41 [PMID: 4655287]
RSC Adv. 2019 Oct 2;9(54):31264-31273 [PMID: 35527962]
Int J Biol Macromol. 2020 Jul 1;154:1265-1275 [PMID: 31726173]
Oral Oncol. 2019 Aug;95:164-169 [PMID: 31345386]
N Engl J Med. 2004 May 6;350(19):1945-52 [PMID: 15128894]
Oral Dis. 2011 Apr;17 Suppl 1:73-84 [PMID: 21382140]
Curr Issues Mol Biol. 2022 Oct 27;44(11):5247-5259 [PMID: 36354669]
Int J Nanomedicine. 2019 Jan 15;14:623-638 [PMID: 30697046]
Curr Opin Oncol. 2022 May 1;34(3):177-184 [PMID: 35249962]
N Engl J Med. 2006 Feb 9;354(6):567-78 [PMID: 16467544]
Arch Med Sci. 2019 Jan;15(1):146-151 [PMID: 30697265]
Int J Med Sci. 2012;9(3):193-9 [PMID: 22408567]
Trends Biotechnol. 2017 Nov;35(11):1074-1087 [PMID: 28734545]
Fam Cancer. 2010 Sep;9(3):321-5 [PMID: 20443067]
Journal Article Review

Word Cloud

Similar Articles

Cited By